Search

Your search keyword '"Rozentale B."' showing total 12 results
Start Over Author "Rozentale B." Language undetermined
12 results on '"Rozentale B."'

1. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Author

Cozzi-Lepri, A., Zangerle, R., Machala, L., Zilmer, K., Ristola, M., Pradier, C., Kirk, O., Sambatakou, H., Fatkenheuer, G., Yust, I., Schmid, P., Gottfredsson, M., Khromova, I., Jilich, D., Flisiak, R., Smidt, J., Rozentale, B., Radoi, R., Losso, M. H., Lundgren, J. D., Mocroft, A., Kundro, M., Schmied, B., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Sedlacek, D., Kronborg, G., Benfield, T., Gerstoft, J., Katzenstein, T., Moller, N. F., Pedersen, C., Ostergaard, L., Wiese, L., Nielsen, L. N., Aho, I., Viard, J. -P., Girard, P. -M., Fontas, E., Duvivier, C., Rockstroh, J., Schmidt, R., Degen, O., Stellbrink, H. J., Stefan, C., Bogner, J., Chkhartishvili, N., Gargalianos, P., Xylomenos, G., Lourida, P., Szlavik, J., Mulcahy, F., Turner, D., Burke, M., Shahar, E., Hassoun, G., Elinav, H., Haouzi, M., Elbirt, D., Sthoeger, Z. M., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Zaccarelli, M., Antinori, A., Acinapura, R., Plazzi, M., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Reiss, P., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Horban, A., Bakowska, E., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Beniowski, M., Mularska, E., Smiatacz, T., Gensing, M., Jablonowska, E., Malolepsza, E., Wojcik, K., Mozer-Lisewska, I., Caldeira, L., Mansinho, K., Maltez, F., Oprea, C., Panteleev, A., Panteleev, O., Yakovlev, A., Trofimora, T., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Jevtovic, D., Tomazic, J., Gatell, J. M., Miro, J. M., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Paredes, R., Tural, C., Puig, J., Bravo, I., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Falconer, K., Thalme, A., Sonnerborg, A., Blaxhult, A., Flamholc, L., Scherrer, A., Weber, R., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Kuznetsova, A., Kyselyova, G., Sluzhynska, M., Gazzard, B., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Orkin, C., Weber, J., Scullard, G., Clarke, A., Leen, C., Thiebaut, R., Burger, D., Peters, L., Matthews, C., Fischer, A. H., Bojesen, A., Raben, D., Kristensen, D., Gronborg Laut, K., Larsen, J. F., Podlekareva, D., Shepherd, L., Schultze, A., Amele, S., Cozzi-lepri, A, Zangerle, R, Machala, L, Zilmer, K, Ristola, M, Pradier, C, Kirk, O, Sambatakou, H, Fätkenheuer, G, Yust, I, Schmid, P, Gottfredsson, M, Khromova, I, Jilich, D, Flisiak, R, Smidt, J, Rozentale, B, Radoi, R, Losso, M. H, Lundgren, J. D, Mocroft, A, Eurosida Study, Group, Castagna, A, Lazzarin, A, AII - Infectious diseases, APH - Aging & Later Life, Infectious diseases, Global Health, Amsterdam institute for Infection and Immunity, Læknadeild (HÍ), Faculty of Medicine (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland, Clinicum, Department of Medicine, and HUS Inflammation Center

Subjects
Male, 0301 basic medicine, observational treatment comparison, HIV Infections, Rate ratio, propensity scores, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Neoplasms, Medicine and Health Sciences, Risk of mortality, AIDS-DEFINING, Pharmacology (medical), Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Original Research, EXPERIENCED, ddc:616, IMMUNODEFICIENCY, Incidence, Health Policy, Incidence (epidemiology), risk of cancer, Middle Aged, 3. Good health, Infectious Diseases, Anti-Retroviral Agents, SAFETY, EXPERIENCED PATIENTS, Cohort, AIDS-DEFINING CANCERS, Female, Historical Cohort, medicine.drug, Adult, Alnæmi, medicine.medical_specialty, animal structures, CANCERS, HIV INTEGRASE INHIBITORS, 030106 microbiology, Antiretroviral Therapy, survival, Risk Assessment, HIV-1-INFECTED PATIENTS, MALIGNANCIES, 03 medical and health sciences, Lyf, Raltegravir Potassium, Internal medicine, PATIENTS, medicine, Humans, COHORT, Highly Active, propensity score, Krabbamein, OPTIMIZED BACKGROUND THERAPY, business.industry, observational treatment, Raltegravir, Survival Analysis, Odds ratio, INFECTED INDIVIDUALS, comparison, 3121 General medicine, internal medicine and other clinical medicine, business
Abstract

Publisher's version (útgefin grein), Objectives There are currently few data on the long‐term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. Methods The EuroSIDA cohort was divided into three groups: those starting RAL‐based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. Results The RAL cohort included 1470 individuals [with 4058 person‐years of follow‐up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non‐AIDS‐related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention‐to‐treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65–1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76–1.72 for RALvs. CONC). Conclusions We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups., EuroSIDA was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no. 260694. Current support includes unrestricted grants from Bristol‐Myers Squibb, Gilead, GlaxoSmithKline LLC, Janssen R&D, Merck and Co. Inc. and Pfizer Inc. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). The study is also supported by a grant (grant number DNRF126) from the Danish National Research Foundation.

Published
2017
Full Text
View/download PDF

2. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

Author

Santos, J. R., Cozzi-Lepri, A., Phillips, A., De Wit, S., Pedersen, C., Reiss, P., Blaxhult, A., Lazzarin, A., Sluzhynska, M., Orkin, C., Duvivier, C., Bogner, J., Gargalianos-Kakolyris, P., Schmid, P., Hassoun, G., Khromova, I., Beniowski, M., Hadziosmanovic, V., Sedlacek, D., Paredes, R., Lundgren, J. D., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., Delforge, M., Florence, E., Vandekerckhove, L., Begovac, J., Machala, L., Jilich, D., Kronborg, G., Benfield, T., Gerstoft, J., Katzenstein, T., Moller, N. F., Ostergaard, L., Wiese, L., Nielsen, L. N., Zilmer, K., Smidt, J., Ristola, M., Aho, I., Viard, J. -P., Girard, P. -M., Pradier, C., Fontas, E., Rockstroh, J., Schmidt, R., Degen, O., Stellbrink, H. J., Stefan, C., Fatkenheuer, G., Chkhartishvili, N., Gargalianos, P., Xylomenos, G., Lourida, P., Sambatakou, H., Szlavik, J., Gottfredsson, M., Mulcahy, F., Yust, I., Turner, D., Burke, M., Shahar, E., Elinav, H., Haouzi, M., Elbirt, D., Sthoeger, Z. M., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Zaccarelli, M., Antinori, A., Acinapura, R., Plazzi, M., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Rozentale, B., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Horban, A., Bakowska, E., Flisiak, R., Grzeszczuk, A., Parczewski, M., Pynka, M., Maciejewska, K., Mularska, E., Smiatacz, T., Gensing, M., Jablonowska, E., Malolepsza, E., Wojcik, K., Mozer-Lisewska, I., Caldeira, L., Mansinho, K., Maltez, F., Radoi, R., Panteleev, A., Panteleev, O., Yakovlev, A., Trofimora, T., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Jevtovic, D., Tomazic, J., Gatell, J. M., Miro, J. M., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Tural, C., Puig, J., Bravo, I., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Falconer, K., Thalme, A., Sonnerborg, A., Flamholc, L., Scherrer, A., Weber, R., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Kuznetsova, A., Kyselyova, G., Gazzard, B., Johnson, A. M., Simons, E., Edwards, S., Johnson, M. A., Mocroft, A., Weber, J., Scullard, G., Clarke, A., Leen, C., Gatell, J., Ledergerber, B., Kirk, O., Peters, L., Matthews, C., Fischer, A. H., Bojesen, A., Raben, D., Kristensen, D., Gronborg Laut, K., Larsen, J. F., Podlekareva, D., Shepherd, L., Schultze, A., Thiebaut, R., Burger, D., Santos, J. R., Cozzi-Lepri, A., Phillips, A., De Wit, S., Pedersen, C., Reiss, P., Blaxhult, A., Lazzarin, A., Sluzhynska, M., Orkin, C., Duvivier, C., Bogner, J., Gargalianos-Kakolyris, P., Schmid, P., Hassoun, G., Khromova, I., Beniowski, M., Hadziosmanovic, V., Sedlacek, D., Paredes, R., Lundgren, J. D., Castagna, A, on behalf of the EuroSIDA study, Group, AII - Infectious diseases, APH - Aging & Later Life, Infectious diseases, Global Health, and Amsterdam institute for Infection and Immunity

Subjects
Male, 0301 basic medicine, antiretroviral therapy-naïve patients, Lopinavir/ritonavir, darunavir, HIV Infections, Antiretroviral therapy-experienced patient, Gastroenterology, antiretroviral therapy-experienced patients, 0302 clinical medicine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Europe, Female, Humans, Middle Aged, Prospective Studies, Treatment Outcome, Pharmacology (medical), 030212 general & internal medicine, atazanavir, Antiretroviral therapy-naïve patient, Health Policy, Lopinavir, Antiretroviral Therapy, Highly Active/methods, ritonavir, Infectious Diseases, Viral load, medicine.drug, medicine.medical_specialty, HIV Infections/drug therapy, Infectious Disease, antiretroviral therapy-naive patients, 03 medical and health sciences, Internal medicine, medicine, Protease inhibitor (pharmacology), Darunavir, business.industry, 030112 virology, Atazanavir, lopinavir, Regimen, Anti-HIV Agents/therapeutic use, Ritonavir, business
Abstract

OBJECTIVES: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens.METHODS: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches.RESULTS: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART.CONCLUSIONS: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.

Published
2018
Full Text
View/download PDF

3. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

Author

Neesgaard, B, Pelchen-Matthews, A, Ryom, L, Florence, E, Peters, L, Roen, A, Svedhem, V, Clarke, A, Benfield, T, Mitsura, V, Moreno, S, Beniowski, M, Begovac, J, Matulionyte, R, Trofimova, T, Elbirt, D, Kundro, M, Vullo, V, Behrens, G, Staub, T, Ragone, L, Vannappagari, V, Lundgren, J, Mocroft, A, Schmied, B, Zangerle, R, Vassilenko, A, Paduto, D, Clumeck, N, De Wit, S, Delforge, M, Vandekerckhove, L, Hadziosmanovic, V, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Gerstoft, J, Katzenstein, T, Pedersen, C, Johansen, IS, Ostergaard, L, Wiese, L, Moller, NF, Nielsen, LN, Zilmer, K, Smidt, J, Ristola, M, Viard, JP, Girard, PM, Fontas, E, Duvivier, C, Degen, O, Stellbrink, HJ, Stefan, C, Goethe, JW, Bogner, J, Fatkenheuer, G, Sambatakou, H, Adamis, G, Paissios, N, Szlavik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Sthoeger, ZM, Monforte, AD, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Hemmer, R, Reiss, P, Reikvam, DH, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak-Was, B, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Kamerys, J, Wojcik, K, Mozer-Lisewska, I, Rozplochowski, B, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Panteleev, A, Panteleev, O, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Borodulina, E, Vdoushkina, E, Miro, JM, Mallolas, J, Martinez, E, Garcia, F, Blanco, JL, Laguno, M, Martinez-Rebollar, M, del Campo, S, Clotet, B, Jou, A, Puig, J, Llibre, JM, Santos, JR, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, MA, Laporte, JM, Falconer, K, Thalme, A, Sonnerborg, A, Treutiger, CJ, Flamholc, L, Scherrer, A, Weber, R, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Gazzard, B, Johnson, AM, Simons, E, Edwards, S, Johnson, MA, Orkin, C, Weber, J, Scullard, G, Leen, C, Phillips, A, Cozzi-Lepri, A, Shepherd, L, Amele, S, Karpov, I, Losso, M, Rockstroh, J, Aho, I, Rasmussen, LD, Wandeler, G, Pradier, C, Chkhartishvili, N, Oprea, C, Kowalska, JD, Guaraldi, G, and Paredes, R

Subjects
two-drug regimens, nucleot(s)ide reverse transcriptase inhibitor-sparing regimens, simplification, HIV, dual therapy, combination antiretroviral treatment
Abstract

Objective: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared with three-drug regimens (3DR) in the EuroSIDA cohort. Design: Multicentre, prospective cohort study. Methods: Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared with those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (

Published
2019

4. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Author

Viard, JP, Gisinger, M, Bhaghani, S, Stellbrink, H, Horban, A, Rockstroh, JK, Lundgren, JD, Kundro, M, Mejia, JMR, Schmied, B, Zangerle, R, Vassilenko, A, Mitsura, VM, Paduto, D, Clumeck, N, De Wit, S, Delforge, M, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Pedersen, C, Johansen, IS, Ostergaard, L, Wiese, L, Moller, NF, Nielsen, LN, Zilmer, K, Smidt, J, Ristola, M, Girard, PM, Fontas, E, Duvivier, C, Behrens, G, Degen, O, Stellbrink, HJ, Stefan, C, Bogner, J, Fatkenheuer, G, Gargalianos, P, Xylomenos, G, Armenis, K, Sambatakou, H, Szlavik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Elbirt, D, Sthoeger, ZM, Monforte, AD, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Staub, T, Hemmer, R, Reiss, P, Reikvam, DH, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak-Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Kamerys, J, Wojcik, K, Mozer-Lisewska, I, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Panteleev, A, Panteleev, O, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Miro, JM, Laguno, M, Martinez, E, Garcia, F, Blanco, JL, Martinez-Rebollar, M, Mallolas, J, Moreno, S, Rodriguez, JM, Clotet, B, Jou, A, Tural, C, Puig, J, Bravo, I, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, MA, Laporte, JM, Falconer, K, Thalme, A, Sonnerborg, A, Treutiger, CJ, Flamholc, L, Scherrer, A, Weber, R, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Gazzard, B, Johnson, AM, Simons, E, Edwards, S, Johnson, MA, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Karpov, I, Losso, M, Lundgren, J, Aho, I, Rasmussen, LD, Svedhem, V, Wandeler, G, Pradier, C, Chkhartishvili, N, Matulionyte, R, Oprea, C, Kowalska, JD, Begovac, J, Miro, J, Guaraldi, G, Paredes, R, Rockstroh, J, Kirk, O, Peters, L, Bojesen, A, Raben, D, Kristensen, D, Laut, K, Larsen, JF, Podlekareva, D, Nykjaer, B, Mocroft, A, Phillips, A, Cozzi-Lepri, A, Amele, S, and Elchen-Matthews, AP

Subjects
Europe, treatment, virus diseases, sustained virological response, continuum of care, HIV/HCV coinfection, digestive system diseases
Abstract

Objectives The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Methods Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Results Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). Conclusions In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Published
2019

5. Liver-related death among HIV/hepatitis C virus-co-infected individuals

Author

Grint, Daniel, Peters, Lars, Rockstroh, Juergen K., Rakmanova, Aza, Trofimova, Tatiana, Lacombe, Karine, Karpov, Igor, Galli, Massimo, Domingo, Pere, Kirk, Ole, Lundgren, Jens D., Mocrofta, Amanda, Losso, M., Kundro, M., Vetter, N., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Kostov, K., Begovac, J., Machala, L., Jilich, D., Sedlacek, D., Nielsen, J., Kronborg, G., Benfield, T., Larsen, M., Gerstoft, J., Katzenstein, T., Hansen, A. B.E., Skinhøj, P., Pedersen, C., Møller, N. F., Ostergaard, L., Dragsted, U. B., Nielsen, L. N., Zilmer, K., Smidt, Jelena, Ristola, M., Katlama, C., Viard, J. P., Girard, P. M., Vanhems, P., Pradier, C., Dabis, F., Neau, D., Duvivier, C., Rockstroh, J., Schmidt, R., Van Lunzen, J., Degen, O., Stellbrink, H. J., Stefan, C., Bogner, J., Fätkenheuer, G., Chkhartishvili, N., Kosmidis, J., Gargalianos, P., Xylomenos, G., Perdios, J., Sambatakou, H., Banhegyi, D., Gottfredsson, M., Mulcahy, F., Yust, I., Turner, D., Burke, M., Shahar, E., Hassoun, G., Elinav, H., Haouzi, M., Sthoeger, Z. M., Monforte, A. D.arminio, Esposito, R., Mazeu, I., Mussini, C., Pristera, R., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Zaccarelli, M., Antinori, A., Acinapura, R., D'Offizi, G., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Rozentale, B., Uzdaviniene, V., Staub, T., Hemmer, R., Reiss, P., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Horban, A., Bakowska, E., Grzeszczuk, A., Flisiak, R., Parczewski, M., Pynka, M., Maciejewska, K., Beniowski, M., Mularska, E., Smiatacz, T., Jablonowska, E., Malolepsza, E., Wojcik, K., Mozer-Lisewska, I., Doroana, M., Caldeira, L., Mansinho, K., Maltez, F., Radoi, R., Oprea, C., Babes, Victor, Rakhmanova, A., Trofimora, T., Khromova, I., Kuzovatova, E., Jevtovic, D., Shunnar, A., Staneková, D., Tomazic, J., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Paredes, R., Tural, C., Puig, J., Bravo, I., Gatell, J. M., Miró, J. M., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Blaxhult, A., Flamholc, L., Thalme, A., Sonnerborg, A., Ledergerber, B., Weber, R., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Elzi, L., Schmid, P., Kravchenko, E., Chentsova, N., Frolov, V., Kutsyna, G., Baskakov, I., Servitskiy, S., Kuznetsova, A., Kyselyova, G., Gazzard, B., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Mocroft, A., Orkin, C., Weber, J., Scullard, G., Fisher, M., Leen, C., Grint, D, Peters, L, Rockstroh, Jk, Rakmanova, A, Trofimova, T, Lacombe, K, Karpov, I, Galli, M, Domingo, P, Kirk, O, Lundgren, Jd, Mocroft, A, for EuroSIDA in, Eurocoord, Lazzarin, A, Castagna, A, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Global Health

Subjects
Liver Cirrhosis, Adult, Male, medicine.medical_specialty, Liver Cirrhosi, Hepatitis C virus, Liver fibrosis, Immunology, Liver-related death, HIV Infections, medicine.disease_cause, Antiviral Agents, HIV/HCV co-infection, Internal medicine, medicine, Humans, Immunology and Allergy, HIV Infection, Cumulative incidence, Prospective Studies, Directly acting antiviral, Causes of death, Antiviral Agent, business.industry, Proportional hazards model, Incidence, Mortality rate, Incidence (epidemiology), Hazard ratio, Liver fibrosi, Directly acting antivirals, Hepatitis C, Chronic, Middle Aged, Hepatitis B, medicine.disease, Female, Liver Failure, Prospective Studie, Infectious Diseases, Population study, business, Human
Abstract

BACKGROUND: Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among HIV/HCV-co-infected individuals. However, the costs of treatment will necessitate prioritization of those at greatest risk of liver-related death (LRD) for therapy. This study aims to provide guidance on who should be prioritized for DAA treatment.METHODS: Three thousand, nine hundred and forty-one HCV antibody-positive PSHREG and FIB-4 are names not acronyms (EuroSIDA) patients with follow-up after 1 January 2000 were included, with causes of death classified using Coding causes of Death in HIV (CoDe) methodology. Crude death rates, competing-risks Cox proportional-hazards models and cumulative incidence functions were used to describe factors associated with LRD.RESULTS: LRD accounted for 145 of 670 (21.6%) deaths in the study population. LRD rates peaked in those aged 35-45 years, and occurred almost exclusively in those with at least F2 fibrosis at baseline. In adjusted Cox models, risk factors for LRD included F4 or F2/F3 fibrosis [sub-distribution hazard ratio (sHR) 6.3, 95% confidence interval (CI) 4.1-9.6; and sHR 2.5, 95% CI 1.5-4.2 vs. F0/F1, respectively), CD4 cell count (sHR 0.83, 95% CI 0.73-0.95 per doubling) and hepatitis B surface antigen-positive (sHR 2.2, 95% CI 1.3-3.5 vs. hepatitis B surface antigen-negative). The 5-year probability of LRD was low in those with F0/F1 fibrosis (sHR 2.2%, 95% CI 1.7-2.9), but substantial in those with F2/F3 and F4 fibrosis (sHR 10.3%, 95% CI 7.6-13.5; and sHR 14.0%, 95% CI 10.3-18.3, respectively).CONCLUSION: Treatment with DAAs should be prioritized for those with at least F2 fibrosis. Early initiation of cART with the aim of avoiding low CD4 cell counts should be considered essential to decrease the risk of LRD and the need for HCV treatment.

Published
2015
Full Text
View/download PDF

7. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

Author

Peters, Lars, Mocroft, Amanda, Soriano, Vincent, Rockstroh, Jã¼rgen, Rauch, Andri, Karlsson, Anders, Knysz, Brygida, Pradier, Christian, Zilmer, Kai, Lundgren, Jens D., Losso, M., Kundro, M., Vetter, N., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Suetnov, O., Clumeck, N., De Wit, S., Delforge, M., Colebunders, R., Vandekerckhove, L., Hadziosmanovic, V., Kostov, K., Begovac, J., Machala, L., Jilich, D., Sedlacek, D., Nielsen, J., Kronborg, G., Benfield, T., Larsen, M., Gerstoft, J., Katzenstein, T., Hansen, A. . B. E., Skinhã¸j, P., Pedersen, C., Ostergaard, L., Zilmer, K., Smidt, Jelena, Ristola, M., Katlama, C., Viard, J. . P., Girard, P. . M., Livrozet, J. M., Vanhems, P., Pradier, C., Dabis, F., Neau, D., Rockstroh, J., Schmidt, R., Van Lunzen, J., Degen, O., Stellbrink, H. J., Staszewski, S., Bogner, J., Fã¤tkenheuer, G., Kosmidis, J., Gargalianos, P., Xylomenos, G., Perdios, J., Panos, G., Filandras, A., Karabatsaki, E., Sambatakou, H., Banhegyi, D., Mulcahy, F., Yust, I., Turner, D., Burke, M., Pollack, S., Hassoun, G., Maayan, S., Vella, S., Esposito, R., Mazeu, I., Mussini, C., Arici, C., Pristera, R., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Chirianni, A., Montesarchio, E., Gargiulo, M., Antonucci, G., Testa, A., Dì€offizi, G., Vlassi, C., Zaccarelli, M., Antorini, A., Gianotti, N., Galli, M., Ridolfo, A., D'arminio Monforte, A., Rozentale, B., Zeltina, I., Chaplinskas, S., Staub, T., Hemmer, R., Reiss, P., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Horban, A., Bakowska, E., Grzeszczuk, A., Flisiak, R., Boron kaczmarska, A., Pynka, M., Parczewski, M., Beniowski, M., Mularska, E., Trocha, H., Jablonowska, E., Malolepsza, E., Wojcik, K., Antunes, F., Doroana, M., Caldeira, L., Mansinho, K., Maltez, F., Duiculescu, D., Rakhmanova, A., Zakharova, N., Buzunova, S., Jevtovic, D., Mokrã¡å¡, M., Stanekovã¡, D., Tomazic, J., Gonzã¡lez lahoz, J., Soriano, V., Labarga, P., Medrano, J., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Paredes, R., Tural, C., Puig, J., Bravo, I., Gatell, J. M., Mirã³, J. M., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Blaxhult, A., Flamholc, L., Ledergerber, B., Weber, R., Francioli, P., Cavassini, M., Hirschel, B., Boffi, E., Furrer, H., Battegay, M., Elzi, L., Kravchenko, E., Chentsova, N., Frolov, V., Kutsyna, G., Servitskiy, S., Krasnov, M., Barton, S., Johnson, A. M., Mercey, D., Phillips, A., Johnson, M. A., Mocroft, A., Murphy, M., Weber, J., Scullard, G., Fisher, M., Leen, C., LAZZARIN, ADRIANO, CASTAGNA, ANTONELLA, Peters, Lar, Mocroft, Amanda, Soriano, Vincent, Rockstroh, Jã¼rgen, Rauch, Andri, Karlsson, Ander, Knysz, Brygida, Pradier, Christian, Zilmer, Kai, Lundgren, Jens D., Losso, M., Kundro, M., Vetter, N., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Suetnov, O., Clumeck, N., De Wit, S., Delforge, M., Colebunders, R., Vandekerckhove, L., Hadziosmanovic, V., Kostov, K., Begovac, J., Machala, L., Jilich, D., Sedlacek, D., Nielsen, J., Kronborg, G., Benfield, T., Larsen, M., Gerstoft, J., Katzenstein, T., Hansen, A. . B. E., Skinhã¸j, P., Pedersen, C., Ostergaard, L., Zilmer, K., Smidt, Jelena, Ristola, M., Katlama, C., Viard, J. . P., Girard, P. . M., Livrozet, J. M., Vanhems, P., Pradier, C., Dabis, F., Neau, D., Rockstroh, J., Schmidt, R., Van Lunzen, J., Degen, O., Stellbrink, H. J., Staszewski, S., Bogner, J., Fã¤tkenheuer, G., Kosmidis, J., Gargalianos, P., Xylomenos, G., Perdios, J., Panos, G., Filandras, A., Karabatsaki, E., Sambatakou, H., Banhegyi, D., Mulcahy, F., Yust, I., Turner, D., Burke, M., Pollack, S., Hassoun, G., Maayan, S., Vella, S., Esposito, R., Mazeu, I., Mussini, C., Arici, C., Pristera, R., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Chirianni, A., Montesarchio, E., Gargiulo, M., Antonucci, G., Testa, A., Dì offizi, G., Vlassi, C., Zaccarelli, M., Antorini, A., Lazzarin, Adriano, Castagna, Antonella, Gianotti, N., Galli, M., Ridolfo, A., D'arminio Monforte, A., Rozentale, B., Zeltina, I., Chaplinskas, S., Staub, T., Hemmer, R., Reiss, P., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Horban, A., Bakowska, E., Grzeszczuk, A., Flisiak, R., Boron kaczmarska, A., Pynka, M., Parczewski, M., Beniowski, M., Mularska, E., Trocha, H., Jablonowska, E., Malolepsza, E., Wojcik, K., Antunes, F., Doroana, M., Caldeira, L., Mansinho, K., Maltez, F., Duiculescu, D., Rakhmanova, A., Zakharova, N., Buzunova, S., Jevtovic, D., Mokrã¡å¡, M., Stanekovã¡, D., Tomazic, J., Gonzã¡lez lahoz, J., Soriano, V., Labarga, P., Medrano, J., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Paredes, R., Tural, C., Puig, J., Bravo, I., Gatell, J. M., Mirã³, J. M., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Blaxhult, A., Flamholc, L., Ledergerber, B., Weber, R., Francioli, P., Cavassini, M., Hirschel, B., Boffi, E., Furrer, H., Battegay, M., Elzi, L., Kravchenko, E., Chentsova, N., Frolov, V., Kutsyna, G., Servitskiy, S., Krasnov, M., Barton, S., Johnson, A. M., Mercey, D., Phillips, A., Johnson, M. A., Mocroft, A., Murphy, M., Weber, J., Scullard, G., Fisher, M., Leen, C., Universitat de Barcelona, and EuroSIDA in EuroCoord

Subjects
Male, HBsAg, HIV opportunistic infections, Epidemiology, Gastroenterology and hepatology, Psychologie appliquée, Gastroenterology, 0302 clinical medicine, middle aged, Medicine, blood/complications/mortality, hepatitis, Hyaluronic Acid, humans, lcsh:Science, 0303 health sciences, Coinfection, adult, Incidence, risk assessment, Sciences bio-médicales et agricoles, 3. Good health, prospective studies, blood/complications, hyaluronic acid, biological markers, male, disease progression, blood, hiv infections, prognosis, human, hepatic encephalopathy, young adult, female, roc curve, follow-up studies, incidence, viral, coinfection, Disease Progression, Infectious diseases, 030211 gastroenterology & hepatology, Biologie, Human, medicine.medical_specialty, Hepatitis, Viral, Human, Prognosi, Acute Liver Failure, Risk Assessment, Follow-Up Studie, 03 medical and health sciences, Liver diseases, Biochemistry, Genetics and Molecular Biology (all), lcsh:R, Biomarker, medicine.disease, Prospective Studie, Agricultural and Biological Sciences (all), Hepatic Encephalopathy, Immunology, lcsh:Q, Biomarkers, lcsh:Medicine, medicine.disease_cause, Hepatitis vírica, HIV Infection, Viral hepatitis, Prospective cohort study, Hepatic encephalopathy, Multidisciplinary, medicine.diagnostic_test, Incidence (epidemiology), Medicine (all), HIV diagnosis and management, Middle Aged, Hepatitis B, Hepatitis C, Infectious hepatitis, HIV clinical manifestations, Female, Research Article, Adult, Hepatitis C virus, 610 Medicine & health, Viral diseases, Infectious Disease Epidemiology, Young Adult, Internal medicine, Biopsy, VIH (Virus), ddc:610, 030304 developmental biology, business.industry, HIV (Viruses), HIV, ROC Curve, business
Abstract

Background:Whereas it is well established that various soluble biomarkers can predict level of liver fibrosis, their ability to predict liver-related clinical outcomes is less clearly established, in particular among HIV/viral hepatitis co-infected persons. We investigated plasma hyaluronic acid's (HA) ability to predict risk of liver-related events (LRE; hepatic coma or liver-related death) in the EuroSIDA study.Methods:Patients included were positive for anti-HCV and/or HBsAg with at least one available plasma sample. The earliest collected plasma sample was tested for HA (normal range 0-75 ng/mL) and levels were associated with risk of LRE. Change in HA per year of follow-up was estimated after measuring HA levels in latest sample before the LRE for those experiencing this outcome (cases) and in a random selection of one sixth of the remaining patients (controls).Results:During a median of 8.2 years of follow-up, 84/1252 (6.7%) patients developed a LRE. Baseline median (IQR) HA in those without and with a LRE was 31.8 (17.2-62.6) and 221.6 ng/mL (74.9-611.3), respectively (p, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013
Full Text
View/download PDF

8. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

Author

Reekie, J1, Reiss, P, Ledergerber, B, Sedlacek, D, Parczewski, M, Gatell, J, Katlama, C, Fätkenheuer, G, Lundgren, Jd, Mocroft, A, Collaborators Losso M, EuroSIDA study g. r. o. u. p., Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Clumeck, N, De Wit, S, Delforge, M, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Machala, L, Rozsypal, H, Nielsen, J, Kronborg, G, Benfield, T, Larsen, M, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Larsen, Od, Oestergaard, L, Zilmer, K, Smidt, J, Ristola, M, Viard, Jp, Girard, Pm, Livrozet, Jm, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Staszewski, S, Bogner, J, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Chiesi, A, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, Vincenzo, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Iacomi, F, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Finazzi, R, Galli, M, Ridolfo, A, Arminio Monforte A, D., Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Valadas, E, Mansinho, K, Maltez, F, Duiculescu, D, Rakhmanova, A, Vinogradova, E, Buzunova, S, Jevtovic, D, Mokrá, M, Staneková, D, Tomazic, J, González Lahoz, J, Soriano, V, Labarga, P, Medrano, J, Moreno, S, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miró, Jm, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, Ma, Karlsson, A, Flamholc, L, Weber, R, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Furrer, H, Battegay, M, Elzi, L, Kravchenko, E, Chentsova, N, Kutsyna, G, Servitskiy, S, Antoniak, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Phillips, A, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Gazzard, B, Arminio Montforte A, D., Lundgren, J, Kirk, O, Friis Møller, N, Cozzi Lepri, A, Bannister, W, Ellefson, M, Borch, A, Podlekareva, D, Kjær, J, Peters, L, Reekie, J, and Kowalska, J.

Subjects
Cyclopropanes, Male, Argentina, Drug Resistance, HIV Infections, HIV Protease Inhibitors, Pyrimidinones, Viral Load, Drug Administration Schedule, Lopinavir, Benzoxazines, Europe, Treatment Outcome, Alkynes, HIV-1, Humans, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, Female, Nevirapine, Prospective Studies, Israel
Abstract

The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long-term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures.Patients starting a nevirapine, efavirenz or lopinavir-based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow-up started ≥ 3 months after initiation of treatment if viral load was500 HIV-1 RNA copies/mL. Durability was measured as discontinuation rate or development/worsening of clinical markers.A total of 603 patients (21%) started nevirapine-based cART, 1465 (51%) efavirenz, and 818 (28%) lopinavir. After adjustment there was no significant difference in the risk of discontinuation for any reason between the groups on nevirapine and efavirenz (P=0.43) or lopinavir (P=0.13). Compared with the nevirapine group, those on efavirenz had a 48% (P=0.0002) and those on lopinavir a 63% (P0.0001) lower risk of discontinuation because of treatment failure and a 31% (P=0.01) and 66% (P.0001) higher risk, respectively, of discontinuation because of toxicities or patient/physician choice. There were no significant differences in the incidence of non-AIDS-related events, worsening anaemia, severe weight loss, increased aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels or increased total cholesterol. Compared with patients on nevirapine, those on lopinavir had an 80% higher incidence of high-density lipoprotein (HDL) cholesterol decreasing below 0.9 mmol/L (P=0.003), but there was no significant difference in this variable between those on nevirapine and those on efavirenz (P=0.39).The long-term durability of nevirapine-based cART, based on risk of all-cause discontinuation and development of long-term adverse events, was comparable to that of efavirenz or lopinavir, in patients in routine clinical practice across Europe who initially tolerated and virologically responded to their regimen.

Published
2010

9. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

Author

Reekie, J, Mocroft, A, Ledergerber, B, Beniowski, M, Clotet, B, van Lunzen, J, Chiesi, A, Pradier, C, Machala, L, Lundgren, Jd, Collaborators Losso M, EuroSIDA Study G. r. o. u. p., Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Clumeck, N, De Wit, S, Delforge, M, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Rozsypal, H, Sedlacek, D, Nielsen, J, Kronborg, G, Benfield, T, Larsen, M, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Oestergaard, L, Zilmer, K, Smidt, J, Ristola, M, Katlama, C, Viard, Jp, Girard, Pm, Livrozet, Jm, Vanhems, P, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, Degen, O, Stellbrink, Hj, Staszewski, S, Bogner, J, Fätkenheuer, G, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, Vincenzo, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Iacomi, F, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Finazzi, R, Galli, M, Ridolfo, A, Monforte, Ad, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Reiss, P, Bruun, J, Knysz, B, Horban, A, Bakowska, E, Prokopowicz, D, Flisiak, R, Boron Kaczmarska, A, Pynka, M, Parczewski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Valadas, E, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Rakhmanova, A, Vinogradova, A, Buzunova, S, Jevtovic, D, Mokrás, M, Staneková, D, Tomazic, J, González Lahoz, J, Soriano, V, Labarga, P, Medrano, J, Moreno, S, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miro, Jm, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, Ma, Karlsson, A, Flamholc, L, Weber, R, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Furrer, H, Battegay, M, Elzi, L, Kravchenko, E, Chentsova, N, Kutsyna, G, Servitskiy, S, Antoniak, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Phillips, A, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Gatell, J, Gazzard, B, Lundgren, J, Kirk, O, Friis Møller, N, Cozzi Lepri, A, Bannister, W, Ellefson, M, Borch, A, Podlekareva, D, Kjaer, J, Peters, L, and Kowalska, J.

Published
2010

10. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

Author

Mocroft, A1, Kirk, O, Reiss, P, De Wit, S, Sedlacek, D, Beniowski, M, Gatell, J, Phillips, An, Ledergerber, B, Lundgren, Jd, Collaborators Losso M, EuroSIDA Study G. r. o. u. p., Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Clumeck, N, Poll, B, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Machala, L, Rozsypal, H, Nielsen, J, Kronborg, G, Benfield, T, Larsen, M, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Oestergaard, L, Zilmer, K, Smidt, J, Ristola, M, Katlama, C, Viard, Jp, Girard, Pm, Livrozet, Jm, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Staszewski, S, Bogner, J, Fätkenheuer, G, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Chiesi, A, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, Vincenzo, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Iacomi, F, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Finazzi, R, Galli, M, Ridolfo, A, d'Arminio Monforte, A, Rozentale, B, Aldins, P, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Bakowska, E, Prokopowicz, D, Flisiak, R, Boron Kaczmarska, A, Pynka, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Valadas, E, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Rakhmanova, A, Vinogradova, E, Jevtovic, D, Mokrás, M, Staneková, D, Tomazic, J, González Lahoz, J, Soriano, V, Martin Carbonero, L, Labarga, P, Moreno, S, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miró, Jm, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, Ma, Karlsson, A, Persson, Po, Flamholc, L, Weber, R, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Furrer, H, Battegay, M, Elzi, L, Kravchenko, E, Chentsova, N, Kutsyna, G, Servitskiy, S, Antoniak, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Phillips, A, Johnson, Ma, Mocroft, A, Murphy, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Gazzard, B, D'Arminio Montforte, A, Lundgren, J, Friis Møller, N, Cozzi Lepri, A, Bannister, W, Ellefson, M, Borch, A, Podlekareva, D, Kjaer, J, Peters, L, Reekie, J, and Kowalska, J.

Published
2010

11. Dialysis and renal transplantation in HIV-infected patients: a European survey

Author

Trullas, Jc1, Mocroft, A, Cofan, F, Tourret, J, Moreno, A, Bagnis, Ci, Fux, Ca, Katlama, C, Reiss, P, Lundgren, J, Gatell, Jm, Kirk, O, Miró, Jm, Collaborators Losso M, EuroSIDA I. n. v. e. s. t. i. g. a. t. o. r. s., Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Clumeck, N, De Wit, S, Delforge, M, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Kronborg, G, Benfield, T, Larsen, M, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Larsen, Od, Oestergaard, L, Zilmer, K, Smidt, J, Ristola, M, Viard, Jp, Girard, Pm, Livrozet, Jm, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Staszewski, S, Bogner, J, Fätkenheuer, G, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Chiesi, A, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, Vincenzo, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Iacomi, F, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Finazzi, R, Galli, M, Ridolfo, A, D'Arminio, A, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Boron Kaczmarska, A, Pynka, M, Parczewski, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Valadas, E, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Rakhmanova, A, Vinogradova, E, Buzunova, S, Jevtovic, D, Mokrás, M, Staneková, D, Tomazic, J, González Lahoz, J, Soriano, V, Labarga, P, Medrano, J, Moreno, S, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Trullas, Jc, Cervera, C, Zamora, L, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, Ma, Karlsson, A, Flamholc, L, Ledergerber, B, Weber, R, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Furrer, H, Battegay, M, Elzi, L, Kravchenko, E, Chentsova, N, Kutsyna, G, Servitskiy, S, Antoniak, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Phillips, A, Johnson, Ma, Mocroft, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Gatell, J, Gazzard, B, D'Arminio Montforte, A, Friis Møller, N, Cozzi Lepri, A, Bannister, W, Ellefson, M, Borch, A, Podlekareva, D, Kjær, J, Peters, L, Reekie, J, and Kowalska, J.

Published
2010

12. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

Author

Bannister, Wendy P., Ruiz, Lidia, Cozzi Lepri, Alessandro, Mocroft, Amanda, Kirk, Ole, Staszewski, Schlomo, Loveday, Clive, Karlsson, Anders, Monforte, Antonella D'Arminio, Clotet, Bonaventura, Lundgren, Jens D., Losso, M., Duran, A., Vetter, N., Karpov, I., Vassilenko, A., Clumeck, N., Dewit, S., Poll, B., Colebunders, R., Kostov, K., Begovac, J., Ristola, M., Machala, L., Rozsypal, H., Sedlacek, D., Nielsen, J., Lundgren, J., Benfield, T., Kirk, O., Gerstoft, J., Katzenstein, T., Hansen, A. B. E., Skinhøj, P., Pedersen, C., Oestergaard, L., Zilmer, K., Smidt, J., Katlama, C., Viard, J. P., Girard, P. M., Livrozet, J. M., Vanhems, P., Pradier, C., Dabis, F., Rockstroh, J., Schmidt, R., Van Lunzen, J., Degen, O., Stellbrink, H. J., Staszewski, S., Bogner, J., Fätkenheuer, G., Kosmidis, J., Gargalianos, P., Xylomenos, G., Perdios, J., Panos, G., Filandras, A., Karabatsaki, E., Sambattakou, H., Banhegyi, D., Mulcahy, F., Yust, I., Turner, D., Burke, M., Pollack, S., Hassoun, G., Maayan, S., Chiesi, A., Esposito, R., Mazeu, I., Mussini, C., Arici, C., Pristera, R., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, Miriam, Chirianni, A., Montesarchio, E., Gargiulo, M., Antonucci, G., Iacomi, F., Narciso, P., Vlassi, C., Zaccarelli, M., Lazzarin, A., Finazzi, R., Galli, M., Ridolfo, A., D'Arminio Monforte, A., Rozentale, B., Aldins, P., Chaplinskas, S., Hemmer, R., Staub, T., Reiss, P., Bruun, J., Maeland, A., Ormaasen, V., Knysz, B., Gasiorowski, J., Horban, A., Prokopowicz, D., Wiercinska Drapalo, A., Boron Kaczmarska, A., Pynka, M., Beniowski, M., Mularska, E., Trocha, H., Antunes, F., Valadas, E., Mansinho, K., Maltez, F., Duiculescu, D., Rakhmanova, A., Vinogradova, E., Buzunova, S., Jevtovic, D., Mokráš, M., Staneková, D., González Lahoz, J., Soriano, V., Martin Carbonero, L., Labarga, P., Clotet, B., Jou, A., Conejero, J., Tural, C., Gatell, J. M., Miró, J. M., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Karlsson, A., Persson, P. O., Flamholc, L., Ledergerber, B., Weber, R., Francioli, P., Cavassini, M., Hirschel, B., Boffi, E., Furrer, H., Battegay, M., Elzi, L., Kravchenko, E., Chentsova, N., Barton, S., Johnson, A. M., Mercey, D., Phillips, A., Johnson, M. A., Mocroft, A., Murphy, M., Weber, J., Scullard, G., Fisher, M., Brettle, R., Gatell, J., Gazzard, B., D'Arminio Montforte, A., Friis Moller, N., Cozzi Lepri, A., Bannister, W., Ellefson, M., Borch, A., Podlevkareva, D., Holkmann Olsen, C., Kjar, J., Peters, L., and Reekie, J.

Subjects
Cyclopropanes, Male, Drug Resistance, HIV Infections, Drug resistance, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, immune system diseases, Immunology and Allergy, 030212 general & internal medicine, Viral, Treatment Failure, 0303 health sciences, Reverse-transcriptase inhibitor, virus diseases, Middle Aged, 3. Good health, Europe, Infectious Diseases, Treatment Outcome, Alkynes, Reverse Transcriptase Inhibitors, Female, Viral load, medicine.drug, Adult, medicine.medical_specialty, Nevirapine, Efavirenz, Genotype, Anti-HIV Agents, Immunology, Microbial Sensitivity Tests, Biology, Benzoxazines, Drug Resistance, Viral, HIV-1, Humans, Mutation, Proportional Hazards Models, 03 medical and health sciences, Internal medicine, medicine, 030306 microbiology, Proportional hazards model, Virology, Confidence interval, Regimen, chemistry
Abstract

OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens. METHODS: NNRTI-naive patients were included who started treatment with nevirapine (NVP) or efavirenz (EFV) with genotypic resistance test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after starting the regimen. Cox models were used to investigate time to virological failure (the first of two values). RESULTS: A total of 759 patients were included (13% antiretroviral-naive): 389 initiated NVP and 370 initiated EFV. Baseline IAS-USA NNRTI resistance mutations were detected in 3%. Using the Rega algorithm (version 7.1) to interpret resistance, 460 (64%) patients had resistance (full or intermediate) to at least one drug they were starting (69% NVP, 60% EFV, P = 0.011); 287 (74%) NVP and 168 (45%) EFV patients experienced virological failure after treatment initiation, P < 0.001. After adjustment for previous antiretroviral use, previous AIDS, year started NNRTI, CD4 cell count (baseline, nadir), viral load (baseline, maximum), and baseline drug resistance (measured by Rega), the relative hazards (EFV versus NVP) of virological failure was 0.50, 95% confidence interval: 0.39-0.65, P < 0.001. At time of virological failure, comparable levels of NNRTI resistance were detected. The K103N mutation emerged more in patients failing EFV and Y181C in patients failing NVP. CONCLUSIONS: NVP may be associated with an inferior virological outcome compared to EFV in NNRTI-naive patients with extensive resistance to other drug classes. The profile of NNRTI resistance mutations when virologically failing an NNRTI-containing regimen appears to depend on the NNRTI the patients fail.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results